Agenus to Participate in September Investor Conferences
September 09 2021 - 8:00AM
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of checkpoint antibodies, cell therapies, adjuvants, and
vaccines designed to activate immune response to cancers and
infections, today announced that Jennifer Buell, PhD, President and
COO of Agenus, will participate in the following upcoming
conferences:
- H.C. Wainwright
23rd Annual Global Investment
Conference presentation will be available on-demand from
Monday, September 13, 2021, starting at 7:00 a.m. ET.
- Baird 2021 Global Healthcare
Conference presentation on Wednesday, September 15, 2021
from 4:20 p.m. to 4:50 p.m. ET.
A webcast and replay for the Baird 2021 Global Healthcare
Conference may be accessed on the company's website at
https://investor.agenusbio.com/events-and-presentations.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing combination approaches that leverage a broad repertoire of
antibody therapeutics, adoptive cell therapies (through its MiNK
Therapeutics subsidiary), adjuvants, and proprietary cancer vaccine
platforms. The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support clinical programs. Agenus is
headquartered in Lexington, MA. For more information, please visit
www.agenusbio.com and our Twitter handle @agenus_bio. Information
that may be important to investors will be routinely posted on our
website and Twitter.
ContactAgenus Investor
RelationsJan Medina,
CFAAgenus781-674-4490Jan.Medina@agenusbio.com
Agenus Media RelationsKimberly HaKKH
Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024